WARRANTNeotherapeutics Inc • April 2nd, 2002 • Pharmaceutical preparations • California
WARRANTNeotherapeutics Inc • April 2nd, 2002 • Pharmaceutical preparations • California
WARRANTNeotherapeutics Inc • April 2nd, 2002 • Pharmaceutical preparations • California
EXHIBIT 10.48 SECURITIES PURCHASE AGREEMENT This Securities Purchaser Agreement (the "Agreement") is made as of March __, 2002 by and between _________________ ("Purchaser"), and NeoTherapeutics, Inc. ("Company"), whereby the parties agree as follows:...Securities Purchase Agreement • April 2nd, 2002 • Neotherapeutics Inc • Pharmaceutical preparations • California
EXHIBIT 10.46 STOCK PURCHASE AGREEMENT This agreement is dated December 10, 2001 between ____________ ("Purchaser"), and NeoTherapeutics, Inc. ("Company"), whereby the parties agree as follows: The Purchaser shall buy and the Company agrees to sell...Stock Purchase Agreement • April 2nd, 2002 • Neotherapeutics Inc • Pharmaceutical preparations
EXHIBIT 4.46 THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN...Neotherapeutics Inc • April 2nd, 2002 • Pharmaceutical preparations • California
EXHIBIT 10.35 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT ("Agreement") is made and entered into as of December 1, 2000 by and between, Dr. Rajesh C. Shrotriya, currently residing at 24571 Santa Clara Avenue, Dana Point,...Executive Employment Agreement • April 2nd, 2002 • Neotherapeutics Inc • Pharmaceutical preparations • California
EXHIBIT 10.39 August 10, 2001 Alvin J. Glasky, PhD Chairman, Chief Executive Officer & Chief Scientific Officer NeoTherapeutics, Inc. 157 Technology Drive Irvine, CA 92618 Dear Dr. Glasky: This letter acknowledges and confirms the terms of the...Neotherapeutics Inc • April 2nd, 2002 • Pharmaceutical preparations
BRIGHTON CAPITAL, LTD. 1888 CENTURY PARK EAST SUITE 1900 LOS ANGELES, CA 90211 (310) 277-6095; FAX: (310) 277-6097Neotherapeutics Inc • April 2nd, 2002 • Pharmaceutical preparations
This letter shall confirm the non-exclusive finder's arrangement between Brighton Capital, Ltd. ("Brighton") and NeoTherapeutics, Inc. ("NEOT") in the event that NEOT proceeds with a debt and/or equity transaction ("Transaction(s)") with a party introduced or procured by Brighton, even though NEOT may have been previously introduced to that party by another. There is no obligation to consummate any Transaction and NEOT can choose to accept or reject any Transaction in its sole and absolute discretion. NEOT acknowledges that there is no guaranty or assurance that any Transaction will take place and that the final legal documentation may contain terms that vary with those set forth on any term sheets. In the event that a Transaction(s) occurs, NEOT agrees to pay Brighton the following at each close (or at Brighton's request, NEOT shall direct the investor to pay the fees directly to Brighton) in cash (a) 6% (six) of all cash amounts received and (b) 10,000 warrants per $1,000,000 funded.
